Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020
Hye-Kyung Jung,
Seung Joo Kang,
Yong Chan Lee,
Hyo-Joon Yang,
Seon-Young Park,
Cheol Min Shin,
Sung Eun Kim,
Hyun Chul Lim,
Jie-Hyun Kim,
Su Youn Nam,
Woon Geon Shin,
Jae Myung Park,
Il Ju Choi,
Jae Gyu Kim,
Miyoung Choi,
Korean College of Helicobacter and Upper Gastrointestinal Research
Affiliations
Hye-Kyung Jung
Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea
Seung Joo Kang
Department of Internal Medicine, Seoul National University Hospital Gangnam Center, Seoul, Korea
Yong Chan Lee
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Hyo-Joon Yang
Division of Gastroenterology, Department of Internal Medicine and Gastrointestinal Cancer Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Seon-Young Park
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
Cheol Min Shin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
Sung Eun Kim
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
Hyun Chul Lim
Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
Jie-Hyun Kim
Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
Su Youn Nam
Center for Gastric Cancer, Kyungpook National University Hospital Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
Woon Geon Shin
Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea
Jae Myung Park
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Il Ju Choi
Center for Gastric Cancer, National Cancer Center, Goyang, Korea
Jae Gyu Kim
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
Miyoung Choi
Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea
Korean College of Helicobacter and Upper Gastrointestinal Research
Helicobacter pylori infection is one of the most common infectious diseases worldwide. Although the prevalence of H. pylori is gradually decreasing, approximately half of the world's population still becomes infected with this disease. H. pylori is responsible for substantial gastrointestinal morbidity worldwide, with a high disease burden. It is the most common cause of gastric and duodenal ulcers and gastric cancer. Since the revision of the H. pylori clinical practice guidelines in 2013 in Korea, the eradication rate of H. pylori has gradually decreased with the use of a clarithromycin-based triple therapy for 7 days. According to a nationwide randomized controlled study conducted by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was mostly due to increased antimicrobial resistance, especially from clarithromycin. The clinical practice guidelines for the treatment of H. pylori were updated according to evidence-based medicine from a meta-analysis conducted on a target group receiving the latest level of eradication therapy. The draft recommendations developed based on the meta-analysis were finalized after an expert consensus on three recommendations regarding the indication for treatment and eight recommendations for the treatment itself. These guidelines were designed to provide clinical evidence for the treatment (including primary care treatment) of H. pylori infection to patients, nurses, medical school students, policymakers, and clinicians. These may differ from current medical insurance standards and will be revised if more evidence emerges in the future.